TrialNature communications2026

Neoadjuvant anti-HER2 antibody-drug conjugate SHR-A1811 in Hormone Receptor-positive, HER2-low Breast Cancer: A Phase 2 Clinical Trial (HELEN-015).

Dechuang Jiao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.